In bladder cancer, KRT5/6 and KRT20 are used as combined markers in immunohistochemical analysis, which is helpful for the clinical evaluation of patient benefits from chemotherapy [36]. This evidence concerns the gene KRT5 and urinary bladder carcinoma.